The approval covers adults with polycythemia vera whose erythrocytosis—the overproduction of red blood cells—is not adequately controlled by existing therapies. Mimrylo is the first approved polycythemia vera treatment designed to mimic hepcidin, a hormone that helps regulate how the body handles iron.

The medicine is administered once a week by subcutaneous injection. By limiting the iron available to make new red blood cells, it is intended to help control hematocrit, the proportion of blood made up of red blood cells.

Why the approval matters

Polycythemia vera is a chronic blood disorder in which the body produces too many red blood cells. The excess cells can make blood thicker and increase the risk of serious cardiovascular problems, including blood clots, stroke and heart attack.

A central treatment goal is keeping hematocrit below 45%. Many patients reach that goal through phlebotomy, a procedure that removes blood from a vein. Some people, however, continue to need frequent phlebotomies despite standard treatment, creating a recurring burden of appointments and blood draws.

What the VERIFY trial found

The FDA said the approval was supported by VERIFY, a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial involving 293 adults with polycythemia vera who required frequent phlebotomies despite ongoing standard-of-care therapy.

Patients received Mimrylo or placebo alongside their existing care during the randomized portion of the study. The FDA reported that 76.9% of patients receiving Mimrylo required no phlebotomies during the weeks 20 through 32 efficacy window, compared with 32.9% of those receiving placebo.

The study defined a clinical response as the absence of phlebotomy eligibility during weeks 20 through 32, with no phlebotomies during that period. That result does not mean the treatment permanently eliminates the need for blood removal or replaces every other part of polycythemia vera care.

How the drug works

Hepcidin is a natural hormone involved in controlling the movement of iron in the body. Mimrylo is designed to imitate hepcidin’s effect. In plain language, reducing the iron available for red-blood-cell production may help limit the excess production that drives erythrocytosis and make hematocrit easier to control.

The trial evaluated Mimrylo together with current standard-of-care treatment. The approval therefore creates an additional option for some patients; it does not automatically replace phlebotomy, cytoreductive medicines or other parts of ongoing care.

Safety and monitoring

The FDA identified injection-site reactions and anemia as the most common adverse reactions. Takeda‘s safety information reports injection-site reactions in 56% of treated patients and anemia in 16%.

Takeda also warns that Mimrylo may increase platelet counts, a condition known as thrombocytosis. The company’s safety information says complete blood counts may need to be checked every two to four weeks after treatment begins and during dose modifications, or as clinically indicated. Changes in platelet counts may require changes to cytoreductive therapy, the Mimrylo dose or treatment itself.

People considering the medicine should discuss weekly injections, blood-count monitoring, injection-site symptoms and possible medication changes with a hematologist or prescribing clinician.

Pregnancy and breastfeeding cautions

Takeda’s safety information warns of possible embryo-fetal toxicity based on animal reproduction studies. That warning does not establish fetal harm in human pregnancy. The company recommends pregnancy testing before treatment for females of reproductive potential and advises effective contraception during treatment and for at least 30 days after the final dose.

Patients are advised not to breastfeed while receiving Mimrylo and for 30 days after the final treatment because of the potential for serious adverse reactions in a breastfed child, including impaired iron absorption.

What remains uncertain

The randomized, placebo-controlled portion of VERIFY lasted 32 weeks, and the study’s open-label extension remains ongoing. The available evidence supports better hematocrit control and fewer phlebotomy-eligibility events, but it does not establish Mimrylo as a cure or prove that it prevents heart attacks, strokes or blood clots.

For adults whose polycythemia vera remains difficult to control, the approval creates a new option to discuss with a specialist. Patients will still need individualized treatment decisions, ongoing blood-count monitoring and follow-up as longer-term safety and durability data develop.

Sources

• FDA approval announcement
• ClinicalTrials.gov VERIFY study record
• Takeda safety and approval information
• OncLive specialist coverage